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http://dx.doi.org/10.1016/j.ymthe.2017.02.004.X-linked myotubular myopathy (XLMTM) results fromMTM1
gene mutations and myotubularin deficiency. Most XLMTM
patients develop severe muscle weakness leading to respiratory
failure and death, typically within 2 years of age. Our objective
was to evaluate the efficacy and safety of systemic gene
therapy in the p.N155K canine model of XLMTM by perform-
ing a dose escalation study. A recombinant adeno-associated
virus serotype 8 (rAAV8) vector expressing canine myotubu-
larin (cMTM1) under the muscle-specific desmin promoter
(rAAV8-cMTM1) was administered by simple peripheral
venous infusion in XLMTM dogs at 10 weeks of age, when
signs of the disease are already present. A comprehensive anal-
ysis of survival, limb strength, gait, respiratory function,
neurological assessment, histology, vector biodistribution,
transgene expression, and immune response was performed
over a 9-month study period. Results indicate that systemic
gene therapy was well tolerated, prolonged lifespan, and cor-
rected the skeletal musculature throughout the body in a
dose-dependent manner, defining an efficacious dose in this
large-animal model of the disease. These results support the
development of gene therapy clinical trials for XLMTM.18These authors contributed equally to this work.
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More than 10,000 diseases are monogenic, with a global prevalence of
approximately 1 in 100.1 Gene therapy holds the promise to treat such
diseases. To date, this approach has not widely translated to treatment
of monogenic disorders affecting skeletal muscle. We report here aMolecular Therapy Vol. 25 No 4 Agene therapy dose-finding study in a large-animal model of a severe
monogenic muscle disease where a single systemic treatment resulted
in dramatic and durable phenotype rescue. Our findings demonstrate
potential application across a wide range of diseases and broadly
translate to human studies.
Gene replacement therapy based on local or systemic administration
of adeno-associated viral (AAV) vectors represents a potential strategy
to treat inherited diseases of skeletal muscle.2 The monogenic muscle
disorder X-linkedmyotubular myopathy (XLMTM;OMIM310400) is
usually fatal and affects about 1 in 50,000male births.3 Affected infants
are typically born floppy with severely weak limbs and respiratory
muscles. Carrier females are occasionally symptomatic.4
Survival requires intensive support, often including gastrostomy
feeding and mechanical ventilation; almost half of affected infants
die before 18 months of age.3 XLMTM is caused by mutations inpril 2017 ª 2017 The American Society of Gene and Cell Therapy. 839
Table 1. Summary Results from 9 Weeks of Age, Pre-infusion, to 17 Weeks of Age across Dosing Groups
Mean Change
Jonckheere-Terpstra
p Value for Trend Corresponding FigureSaline Low Dose Mid Dose High Dose
Neurological Function
NAS (1–10) 3 1 0.3 0.7 <0.01 Figures 2A–2D
Reflex score (0–4) 0.36 0.13 0.37 0.63 <0.01 Figures 2E–2H
Limb Strength
Forelimb extension (N,m/kg) 0.007 0.003 0.14 0.01 <0.01 Figures 3A–3D
Forelimb flexion (N,m/kg) 0.017 0.004 0.055 0.052 0.01 Figures 3E–3H
Hindlimb extension (N,m/kg) 0.01 0.04 0.11 0.12 0.03 Figures 3I–3L
Hindlimb flexion (N,m/kg) 0.014 0.021 0.085 0.007 <0.01 Figures 3M–3P
Walking Gait
Stride velocity (cm/s) 15.3 4.2 70.1 57.4 0.03 Figures 4A–4D
Stride length (cm) 1.6 12 27.4 26.2 <0.01 Figures 4E–4H
Respiratory Function
Peak inspiratory flow (mL/s) 13.4 46.7 129.3 176.3 <0.01 Figures 5A–5E
Molecular TherapytheMTM1 gene, resulting in deficiency or dysfunction of the enzyme
myotubularin, a 3-phosphoinositide phosphatase.5 The lack of myo-
tubularin seen in XLMTM profoundly affects skeletal muscles and
produces a distinctive histopathology in animal models and in pa-
tients: myofibers are smaller and organelle organization is abnormal.6
No disease-modifying therapies are currently available for patients,
but initial AAV-mediated gene transfer experiments in animal
models demonstrated dramatic phenotype improvement and sug-
gested that effective treatment might be possible for XLMTM.7,8
A canine model of XLMTM provided the first opportunity to test re-
combinant adeno-associated virus serotype 8 (rAAV8) gene transfer
in a large-animal model of this disease at a volume that could be
infused in clinical practice. In a previous pilot study, we reported
that a locoregional infusion of an rAAV8 vector expressing canine
MTM1 (rAAV8-cMTM1) into XLMTM puppies halted progression
of the disease, dramatically improved muscle strength, and markedly
extended survival.7
The goals of the present randomized, blinded study of escalating
systemic doses of rAAV8-cMTM1 in XLMTM dogs were to estab-
lish a dosing regimen using validated endpoints while assessing
safety and biodistribution. We report long-term correction of
skeletal muscle pathology following a single infusion of rAAV8-
cMTM1 at doses compatible with clinical applications. At therapeu-
tic doses, rAAV8-cMTM1 was well tolerated and led to expression
of myotubularin protein in skeletal muscles, with repaired myofiber
pathology. Most importantly, treatment with rAAV8-cMTM1 led
to extended survival, recovery of neurological function, and im-
provements in peak airflow velocity, limb strength, and walking
gait without safety concerns. These data provide strong rationale
for moving therapeutic doses of rAAV8-MTM1 into clinical
studies.840 Molecular Therapy Vol. 25 No 4 April 2017RESULTS
Systemic Gene Therapy Prolongs Survival and Corrects the
Clinical Status of XLMTM Dogs in a Dose-Dependent Manner
We injected three escalating doses of rAAV8-cMTM1 (0.3E14,
2E14, and 5E14 vg/kg) in the cephalic vein of XLMTM dogs
(n = 3 per dose) at 10 weeks of age, and saline in age-matched mutant
and normal littermates (n = 6 per group) as controls. We decided to
include males and females in the present study. Group assignment
randomization (Table S1) resulted in three males and three females
in the saline-infused normal control group, one male hemizygous
and five females homozygous for the MTM1 mutation in the saline-
infused XLMTM group, two males hemizygous and one female ho-
mozygous in the low-dose group, and the mid- and high-dose groups
consisted of all hemizygous mutant males. The response of animals to
the treatment was studied over a 9-month period (Figure S1), and
summary results of outcome measures are presented in Table 1.
Dosing trends, measured by the Jonckheere-Terpstra test, were calcu-
lated from the mean change in pre-infusion (9 weeks of age) to post-
infusion (17 weeks of age) values. The 17-week time point was chosen
because this was the only time when all saline-infused XLMTM dogs
survived. Significant trends were found in every clinical and physio-
logical readout (survival, neurological function, limb strength, gait,
and respiratory function), as described below.
Prolonged Survival
Untreated, XLMTM dogs harboring a p.N155K mutation in MTM1
become symptomatic at around 8 weeks of age, and muscular weak-
ness progresses until approximately 5 months of age, when animals
can no longer ambulate (Movie S1), necessitating humane euthanasia.
Intravenous administration of rAAV8-cMTM1 at mid (2E14 vg/kg)
and high (5E14 vg/kg) doses prolonged ambulation (Movie S2) and
conferred long-term survival until the end of the 9-month observa-
tion period, whereas rAAV8-cMTM1 at low dose (0.3E14 vg/kg)
Figure 1. MTM1 Gene Replacement with Systemic rAAV8 at Dose above
2E–14 vg/kg Markedly Extends Survival of XLMTM Dogs
Kaplan-Meier survival curves for dogs (n = 21) in one of five groups: wild-type (WT) or
carrier (phenotypically normal, teal symbols, n = 6) comparison controls, or XLMTM
dogs given a single venous infusion of saline (brown symbols, n = 6), 0.3E14
rAAV8-cMTM1 (low dose, purple symbols, n = 3), 2E14 rAAV8-cMTM1 (mid dose,
red symbols, n = 3), or 5E14 vg/kg rAAV8-cMTM1 (high dose, blue symbols, n = 3).
Jonckheere-Terpstra analysis was used to test for a dosing trend across groups.
www.moleculartherapy.orgdid not provide a major survival benefit over that of saline infusion,
p = 0.0001 (Figure 1).
Neurological Improvement
Dogs were assessed for improvement in neurological function using a
validated clinical scoring instrument developed for dogs, the neurolog-
ical assessment score (NAS) (Figure 2A).9 Results clearly demonstrated
a dose-dependent effect of rAAV8-cMTM1 (p < 0.01) (Figures 2A–D;
Table S1). Before infusion, XLMTM dogs scored slightly lower than
normal controls (Figure 2C). After infusion, at the 17-week time point,
NAS declined markedly in saline- and low-dose-infused dogs, whereas
normal controls and XLMTM dogs given mid- or high-dose rAAV8-
cMTM1 achieved comparable neurological scores (Figure 2D;
Movie S3). At the end of the 9-month study, XLMTM dogs in the
mid- and high-dose groupsmaintained neurological scores comparable
with their age-matched normal controls (Figure 2B; Table S2), with
dogs treated at highdose performing the best of the three dosing groups.
To evaluate effects of rAAV8-cMTM1 on spinal reflexes, we recorded a
clinical composite score of individual segmental reflexes (scored 0–4)
for all dogs (Figure 2E). Similar to NAS, a dose-response was observed,
with composite reflex scores improving quickly and dramatically be-
tween 9 and 17 weeks of age in the mid- and high-dose groups
(p < 0.01) (Figure 2F; Table 1). At the pre-infusion time point, XLMTM
dogs exhibited composite reflex scores lower thannormal controls (Fig-
ure 2G). By 17 weeks, reflex function declined in saline- and low-dose-
infused XLMTM dogs, and improved in dogs given mid- or high-dose
rAAV8-cMTM1 (Figure 2H). At the study conclusion, XLMTM dogs
receiving mid- or high-dose rAAV8-cMTM1 achieved reflex scores
comparable with their age-matched controls.
Strength Improvement
In vivo isometric torque was repeatedly measured in the forelimbs
and hindlimbs of anesthetized dogs from each cohort. Results (TableS3) demonstrated that saline infusion failed to halt progressive weak-
ness, with deficiencies most notable in the muscles that pull the paw
upward from the ground, mainly the extensor carpi radialis, a fore-
limb extensor, and the cranial tibialis, a hindlimb flexor (Figures
3A and 3M). In contrast, mid- and high-dose rAAV8-cMTM1 led
to increased strength (p < 0.01), most notably in these same muscles
(e.g., the extensor carpi radialis and cranial tibialis; Figures 3B–3D
and 3N–3P, respectively).
In the forelimb (Figures 3A–3H) muscles that pull the paw upward
from the ground, the forelimb extensors, a clear dose-response to
rAAV8-cMTM1was observed at 17weeks of age (p < 0.01; Figure 3D).
In the mid- and high-dose-infused dogs, torque values more than
doubled those of saline-treated dogs. In comparison, the dose-
response observed in forelimb extension was less pronounced in fore-
limb flexion (muscles that push the paw toward the ground, such as
the flexor carpi radialis). Forelimb flexion torque in the low-dose
cohort did not improve, whereas the mid- and high-dose group
both improved to levels comparable with normal (p = 0.01;
Figure 3H).
In the hindlimb, a similar dose-response trend was observed in the
muscles that pull the paw upward from the ground, primarily the
cranial tibialis and long digital extensor (Figures 3I–3P). In these
hindlimb flexor muscles, a robust dose-response was observed at
17 weeks of age (p < 0.01; Figure 3P). Torque values measured in
dogs given mid- and high-dose rAAV8-cMTM1 more than doubled
those of saline-treated dogs. In comparison, the dose-response trend
observed in hindlimb extension (p = 0.03; Figure 3I) was not as
marked as the response observed in hindlimb flexion.
Together, the muscle performance data indicate that rAAV8-cMTM
infusion at mid and high dose significantly improved torque produc-
tion in forelimb and hindlimb flexion and extension of treated
XLMTM dogs to values close to normal dogs.
Gait Improvement
To evaluate effects of rAAV8-cMTM1 on limb function and
mobility, we evaluated gait while dogs walked over an instru-
mented carpet capturing spatiotemporal data.10,11 Results show a
dose-dependent effect on both gait speed (p = 0.03) and stride
length (p < 0.01) (Movie S4; Table S4). At the pre-infusion assess-
ment, XLMTM dogs demonstrated abnormally slow walking veloc-
ities with shortened stride lengths (Figure 4), consistent with our
previous natural history data.11 Over the ensuing 7 weeks, walking
gait in saline-infused XLMTM dogs continued to decline; by
17 weeks of age, half of the saline-infused affected dogs grew too
weak to walk repeatedly over the instrumented carpet, and only
three of the six saline-infused dogs could be evaluated. In contrast,
XLMTM dogs infused with rAAV8-cMTM1 showed gait improve-
ment, but only in dogs given mid (n = 3) or high (n = 3) vector
doses. These dogs achieved gait speed and stride lengths com-
parable with that of their normal littermates (Figures 4B and 4F;
Movie S4).Molecular Therapy Vol. 25 No 4 April 2017 841
Figure 2. MTM1 Gene Replacement with Systemic
rAAV8 Halts the Progressive Decline in Global
Neurological Function and Spinal Reflexes
(A) Method of the NAS. (B) NAS over time. (C and D)
Group comparison of NAS before (C) and 7 weeks after
(D) infusion. Trend analysis indicated a significant dose-
response in NAS (p < 0.01). (E) Method of spinal reflex
assessment. (F) Reflex scores over time. (G and H) Group
comparison of reflex scores before (G) and 7 weeks after
(H) infusion. Trend analysis indicated a significant dose-
response in spinal reflex scores (p < 0.01). Jonckheere-
Terpstra analysis was used to test for a dosing trend
across groups. Data are presented as mean and SEM.
Molecular TherapyRespiratory Function Improvement
XLMTM in children is strongly associated with neonatal hypotonia
and respiratory failure;12 an analogous phenotype is observed in
XLMTM dogs.11,13 To test for dose effects of rAAV8-cMTM1 on
respiratory function, we evaluated airflow exchange in anesthetized
dogs using published protocols.11,13We previously observed that after
giving a chemical respiratory stimulant, peak inspiratory flow is lower
in XLMTM compared with normal dogs. In the present study, trend
analysis of peak inspiratory flow indicated a dose effect of rAAV8-
cMTM1 (p < 0.01) (Table S4). Whereas the peak inspiratory flow
declined in saline- or low-dose-infused XLMTM dogs over the
37-week study, we found that values increased to levels comparable
with controls in dogs receiving mid and high doses of rAAV8-
cMTM1 (Figures 5A–5D). Respiratory rate values (Figures 5E–5H)
in mid- and high-dose groups achieved levels comparable with
control dogs at 17 weeks, but these changes were not significantly
different from pre-infusion values.842 Molecular Therapy Vol. 25 No 4 April 2017Intravenous Administration of rAAV8-
cMTM1 Corrects XLMTMMuscle Pathology
throughout the Body
To measure the extent of pathology in XLMTM
dogs, we scored histological findings based on
the proportion of myofibers with typical path-
ological features characteristic of XLMTM
including small size, abnormal localization of
cellular organelles, and central nucleation.
Prior to treatment at 10 weeks of age, baseline
disease pathology appeared comparable among
all XLMTM dogs (Figure 6A; Figure S2; Table
S5). Saline-treated mutant dogs developed se-
vere muscle pathology consistent with the natu-
ral history of disease progression.6,11 Following
intravenous infusion of rAAV8-cMTM1, dogs
that received the low dose failed to show
improvement in disease pathology at later time
points. In contrast, dogs that received either
the mid or high dose of rAAV8-cMTM1
demonstrated near-complete reversal of
XLMTM-related pathology, displaying essen-
tially normal skeletal muscle histology in themajority of samples evaluated at 17 and 25 weeks of age and at eutha-
nasia (Figures 6B–6E).
To assess whether rAAV8-cMTM1 treatment can repair the ultra-
structural defects observed in myofibers, we evaluated skeletal mus-
cles from treated and untreated dogs by electron microscopy (EM).
In normal muscle, transverse-tubules are typically located with a
pair of terminal cisternae (bulbous enlarged areas of the sarcoplasmic
reticulum) to form an arrangement called a triad. Results (Figure 6;
Table S5) indicate that a single infusion of rAAV8-cMTM1 led to
normalization of disrupted sarcotubular architecture (as indicated
by the number of triad structures present in the myofiber) in the
mid- and high-dose-infused dogs, whereas lower numbers of triads
were found in the low-dose- and saline-infused XLMTM dogs. These
findings demonstrate that rAAV8-cMTM1 exerts a dose-dependent
effect to repair a structural defect in the contractile apparatus associ-
ated with XLMTM.
Figure 3. Progressive Loss of Limb Muscle Strength Is Ameliorated with Increasing Doses of rAAV8-cMTM1
(A) In vivomethod of forelimb extensor strength testing in anesthetized dogs. A nerve stimulator delivers electrical frequencies from 1 to 150 Hz tomuscles that extend, or pull,
the front paw up away from the ground. A transducer captures the torque generated when the paw pushes on the force plate. (B–D) Forelimb extensor torque over time (B),
before infusion (C), and 17 weeks after infusion (D). Trend analysis indicated a significant dose-response in forelimb extensor torque (p < 0.01). (E) In vivo method of forelimb
flexor strength testing in dogs. Stimulation frequencies from 1 to 150 Hz activate muscles that push the front paw against the ground. A transducer captures the torque
generated when the paw pushes on the force plate. (F–H) Forelimb flexor torque over time (F), before infusion (G), and 17 weeks after infusion (H). Trend analysis indicated a
significant dose-response in forelimb flexor torque (p = 0.01). (I) In vivo method of hindlimb extensor strength testing. Stimulation frequencies from 1 to 110 Hz activate
muscles that extend, or push, the hind paw against the ground. A transducer captures the torque generated when the paw pushes against the force plate. (J–L) Hindlimb
extensor torque over time (J), before infusion (K), and 17 weeks after injection (L). Trend analysis indicated a significant dose-response in hindlimb extensor torque (p = 0.03).
(M) In vivo method of hindlimb flexor strength testing. Stimulation frequencies from 1 to 110 Hz activate muscles that flex, or pull, the hind paw away from the ground. A
transducer captures the torque generated when the paw pulls on the force plate. (N–P) Hindlimb flexor torque over time (N), before infusion (O), and 17 weeks after infusion
(P). Trend analysis indicated a significant dose-response in hindlimb flexor torque (p < 0.01). For all figures, strength is presented as maximal isometric torque normalized to
body weight (kg). The Jonckheere-Terpstra analysis was used to test for a dosing trend across groups. Data are presented as mean and SEM.
www.moleculartherapy.orgDose-Dependent Vector Biodistribution and Transgene
Expression in Tissues of Treated Dogs
Weanalyzed vector biodistribution in 68 tissues and organs throughout
the body of XLMTM dogs. The rAAV8-cMTM1 vector transduced
most tissues with the exception of brain, pancreas, and thymus (Fig-
ure 7A). In skeletal muscles, vector genomes (vg) were distributed ho-
mogenously and increased with dosage of rAAV8-cMTM1 (Figure S3;
Table S6). In the mid-dose-treated cohort, vector copy number (VCN)ranged from0.4± 0.1 vg/diploid genome (dg) in the diaphragm to 1.4±
0.4 vg/dg in the biceps femoris, whereas in dogs given high-dose
rAAV8-cMTM1, VCN ranged from 1.3 ± 0.9 in the cranial tibialis to
3.2 ± 1.4 in intercostal muscles. VCN in heart and liver of high-dose-
treated dogs was 2.7 ± 1.0 and 4.5 ± 1.6 vg/dg, respectively.
The vector biodistribution pattern generally correlated with transgene
expression. Total MTM1 mRNA (Table S7) and myotubularinMolecular Therapy Vol. 25 No 4 April 2017 843
Figure 4. Walking Gait Improves with Increasing
Doses of rAAV8-cMTM1
Dogs walked repeatedly over an instrumented carpet
to capture spatiotemporal measures of gait. (A) Sen-
sors imbedded in the carpet calculate walking speed.
(B) Gait speed comparisons between treatment
groups over the 37 weeks of study. (C) Gait speed
before rAAV8-cMTM1 infusion demonstrates reduced
gait speed in all XLMTM groups compared with the
normal group. (D) Gait speed 17 weeks after infusion
demonstrates improvement in mid- and high-dose-
infused XLMTM dogs, with values comparable with
normal dogs at this time point, whereas saline and
low-dose dogs continue to demonstrate reduced gait
speed compared with normal dogs. Trend analysis
indicated a significant dose-response in gait speed
(p = 0.03). (E) A single stride length. (F) Stride length
comparisons between treatment groups over the
37 weeks of study. (G and H) Stride length
among treatment groups before infusion (G) and
17 weeks after infusion (H). Trend analysis indicated a
significant dose-response in stride length (p < 0.01).
The Jonckheere-Terpstra analysis was used to test
for a dosing trend across groups. Data are presented
as mean and SEM.
Molecular Therapyprotein levels (Table S8) were quantified in various tissues, including
nine skeletal muscles, five regions of the heart (left and right ventri-
cles, left and right atria, and papillary region), and seven other organs
(liver, lung, bladder, stomach, spleen, kidney, and brain). The level of
mRNA transcripts derived from the vector and the total level of
MTM1 mRNA (endogenous + vector-derived) was higher in skeletal
muscles and heart compared with other tissues of rAAV8-cMTM1-
treated dogs, reflecting the muscle specificity of the desmin promoter.
Transgenic myotubularin protein was found mostly in muscles, and
its expression level increased with increasing doses of rAAV8-
cMTM1, ranging from 15% of endogenous wild-type (WT)myotubu-
larin level in the diaphragm to about 50% in other skeletal muscles of
XLMTM dogs treated with the mid dose. In dogs receiving the high844 Molecular Therapy Vol. 25 No 4 April 2017dose, myotubularin level reached 80% of the
endogenous level in the tibialis cranialis, 220%
in the intercostal muscles, and 440% in whole
heart (mean range in the five cardiac regions:
260%–770%; Figures 7B and 7C; Figure S3;
Table S8). These findings indicate that rAAV8-
cMTM1 distributed throughout the body of
XLMTM dogs in a dose-dependent manner,
and the amount of myotubularin produced in
skeletal muscles in the mid-dose-treated group
was sufficient to correct the disease phenotype.
Safety Profile of rAAV8-cMTM1 Vector
Delivery in XLMTM Dogs
Cephalic venous infusion was well tolerated
without adverse events in all dogs. We foundno significant changes in complete hematology counts, serum electro-
lytes, or kidney function and liver function parameters measured
weekly following rAAV8-cMTM1 infusion. In addition, no adverse
effects related to the experimental procedures were observed in dogs.
Because high overexpression of myotubularin in the heart of Mtm1
knockout (KO) mice was reported to induce cardiac lesions,7 we as-
sessed potential off-target effects of rAAV8-cMTM1 on heart function
using two-dimensional echocardiography with Doppler imaging
(Table S9) and histology. After referencing published nomograms,14
we estimated that an ejection fraction >60% was normal for left ven-
tricular (LV) systolic function. Saline-infused XLMTM dogs showed
normal ejection fraction at 17–18 weeks (range 62%–78%), although
Figure 5. Peak Inspiratory Flow Improves with
Increasing Doses of rAAV8-cMTM1
(A) Representative screen shot of a single breath; arrow
indicates peak inspiratory flow. (B) Comparison of peak
inspiratory flow in all treatment groups from 9 (pre-infu-
sion) to 37 weeks. (C and D) Peak inspiratory flow prior to
(C) and 17 weeks after (D) rAAV8-cMTM1 infusion. (E)
Representative screen shot of a train of single breaths
over time. (F) Comparison of respiratory rate across all
treatment groups from pre-infusion up to 37 weeks. (G)
Respiratory rate prior to infusion. (H) Respiratory rate
at 17 weeks. Trend analysis indicated a significant dos-
e-response in peak inspiratory flow (p < 0.01). The
Jonckheere-Terpstra analysis was used to test for a
dosing trend across groups. Data are presented as mean
and SEM.
www.moleculartherapy.orgthey had abnormalities in diastolic function as assessed by measuring
mitral inflow velocity ratios (E/A), mitral valve (MV) annulus tissue
velocity (e0), and intraventricular relaxation time (IVRT). At
17–27 weeks, the female carriers showed mild decrease in LV systolic
function (52% and 57%) compared with the male controls and saline-
infused XLMTM dogs (range 61%–86%). The LV systolic function
in the carrier/control group normalized by 38–52 weeks (range
64%–78%). Of the dogs receiving rAAV8-cMTM1, one XLMTM
dog that received low-dose rAAV8-cMTM1 also had a mild decrease
in ejection fraction (54%) at 17–18 weeks, which further decreased at
27 weeks (45%) and was associated with mild diastolic dysfunction.
This dog did not receive further echocardiograms. In dogs receiving
either the mid- and high-dose rAAV8-cMTM1, no abnormalities of
LV systolic function were detected between 17 and 27 weeks, although
one dog that received mid-dose rAAV8-cMTM1 had borderlinenormal systolic function (59.9%) with normal
diastolic function. Wall thickness was normal-
ized to body weight in the growing dogs.
Increased wall thickness of the LV septal and
posterior wall was observed in two dogs (at 27
and 38 weeks) that received mid-dose rAAV8-
cMTM1. The increase in wall thickness was
also observed in dogs at 18 weeks that
received the high-dose rAAV8-cMTM1, and
the increase in septal wall thickness persisted at
27 weeks despite normalization of posterior
wall thickness.
Lightmicroscopic evaluation of heart slides taken
from vehicle control, untreated control, and
AAV-MTM1-treated XLMTM dogs were inde-
pendently evaluated by a veterinary pathologist.
Findings revealed minimal to mild infiltration
of mononuclear and/or mixed inflammatory
cells on the epicardium, myocardium, and/or
endocardium of the heart. These findings
occurred in a few control and treated animalsin a non-dose-related manner and were not associated with degenera-
tion,mineralization, loss of cardiomyocytes, andmyocardial fibrosis or
other cardiomyopathic changes. Similar cellular infiltrates in the heart
were considered incidental, naturally occurring background changes in
laboratory dogs.
Intravenous Administration of rAAV8-cMTM1 Induces No
Humoral or Cytotoxic Immune Response Directed toward the
Transgene Product in Mutant Dogs
We analyzed the humoral and cellular immune responses of XLMTM
dogs toward the vector capsid and canine myotubularin at various
time points prior to and following intravascular vector administration
(Figure S4). Neutralizing antibodies (NAB) and IgG titers specific to
rAAV8, and antibodies against myotubularin were measured in dog
sera before and after delivery of the three doses of rAAV8-cMTM1Molecular Therapy Vol. 25 No 4 April 2017 845
Figure 6. A Single Infusion of rAAV8-cMTM1 Can
Reverse Skeletal Muscle Pathology
(A) Representative micrographs of vastus lateralis muscle
samples taken from normal and XLMTM dogs at
10 weeks (pre-infusion) and at the post-infusion intervals
indicated. Myofiber size and nuclear position is illustrated
on H&E staining, as shown on the red-stained images.
NADH staining, as shown on the blue-stained images,
illustrates organelle distribution. The presence and orga-
nization of triad structures (arrows) are best illustrated on
the black-and-white electron micrographs. Scale bar,
40 mm. (B–E) Histological findings were quantified to
determine (B) muscle pathology scores, (C) the percent-
age of myofibers with centrally located nuclei, (D) the
percentage of myofibers with abnormal organelle distri-
bution, and (E) the MinFeret diameter. One-way ANOVA
followed by Bonferroni’s multiple comparison post-test
was used to compare results between groups. Data are
presented as mean and SEM.
Molecular Therapyand in the control group. NAB and IgG titers against the AAV8 capsid
increased 2 weeks after vector injection and remained elevated
through the end of the study in all treated animals. No clear differ-
ences in the level of antibodies were noted among dose groups.
Conversely, myotubularin-specific IgG remained undetectable in all
treated animals. Cell-mediated immune responses against the vector
or the transgene product were tested regularly over a period of
218 days after vector administration. No T cells specific to the vector
capsid or to myotubularin were detected in the blood of treated dogs.
DISCUSSION
The present study was designed to model systemic dosing of rAAV8-
MTM1 gene therapy in a future clinical trial in patients. It was
conducted in a large cohort of XLMTM dogs to determine the vector
safety profile, measure efficacy with clinically relevant endpoints,846 Molecular Therapy Vol. 25 No 4 April 2017analyze vector biodistribution, and examine
immunological responses to both the vector
and the transgene product across three doses.
Our study demonstrates that AAV8-mediated
gene therapy can effectively correct the entire
skeletal musculature in a large-animal model
of an inherited fatal myopathy following a single
intravenous vector administration, with wide-
spread implications for the treatment of other
congenital muscle diseases.
The feasibility of MTM1 gene replacement with
rAAV was previously tested in Mtm1 KO mice
by intramuscular and tail vein injections,7,15
and then in a pilot study in XLMTM dogs by
locoregional infusion of a hindlimb,7 showing
long-term benefits. The injection of a single
dose of rAAV8-cMTM1 under high pressure
into the saphenous vein of 9-week-old dogs re-sulted in the correction of the pathology in the infused hindlimb,
but also in distal muscles, with an unexpected systemic effect and pro-
longation of lifespan.7 This whole-body phenotypic correction varied
among dogs, probably depending on the amount of vector that went
into the general circulation after tourniquet release. In the present
study, we tested a more clinically relevant route of administration by
simple injection of rAAV8-cMTM1 into a peripheral vein, the cephalic
vein of the upper limb, and performed a dose-finding study in
XLMTM dogs at 10 weeks of age when pathology is well established
in skeletal muscles.11 Because of both ethical and cost considerations,
we includedMTM1mutant hemizygousmale andhomozygous female
XLMTM dogs, and animals were randomized into the various study
groups. In our colony, homozygous females present a phenotype
similar to that of hemizygous males. Both male and female XLMTM
dogs develop muscle weakness, gait abnormalities, and neurological
Figure 7. A Single Infusion of rAAV8-cMTM1 Yielded
Whole-Body Vector Biodistribution, Leading to
Myotubularin Expression that Increased with Dose
(A) Schematic depiction of canine anatomy showing a
subset of muscles and organs analyzed at necropsy for
the presence of rAAV8 vg. PCR-detected vg per canine
dg from each muscle and organ were averaged within
each treatment group, converted to a color gradient and
overlaid on the dogs’ anatomy. (B) Using similar meth-
odology, we used semiquantitative western blots to
measure transgenic MTM1 protein expression. Expres-
sion levels were averaged for individual muscles and or-
gans within each treatment group and converted to a
color gradient with normal endogenous levels of MTM1
protein in each tissue assigned a value 1. (C) Key for
individual muscles shown in (A) and (B).
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randomization led to non-equal distribution with regard to sex, with
female dogs more heavily represented in the saline group and only
one female included in the low-dose group. Therefore, sex-related
phenotype differences in the low-dose or saline groups cannot be ruled
out; however, they did not confound any of the readouts in the mid-
and high-dose groups because these cohorts consisted of all males.
The first major finding reported here is the dose-dependent
improvement in strength to levels approaching normal following
MTM1 gene transfer. Severe weakness is the key clinical character-
istic of the disease, and thus muscle strength represents the most
important readout. We observed improved muscle torque perfor-
mance in both forelimbs and hindlimbs of XLMTM dogs to levels
comparable with normal dogs, indicating complete rescue of muscle
function following mid and high dose of rAAV8-cMTM1. Some of
the functional results (forelimb and hindlimb flexion torque, stride
velocity, and length) indicate that the mid dose is equal to, or some-
times better, than the high-dose readouts at 17 weeks, a time when
all four cohorts could be measured. However, the NAS, forelimb
extension torque, hindlimb extension torque, and peak inspiratory
flow values at 17 weeks indicate that 5E14 vg/kg of vector resulted
in slightly better responses. Despite these variations, statistical ana-
lyses detected positive dosing trends in the majority of functional
assessments as indicated in Table 1, although a clear ceiling to
the response at the mid dose cannot be confidently determined.
Importantly, our study identifies systemic doses of rAAV8
(2E14 and 5E14 vg/kg) that led to a reversal of the disease
phenotype in XLMTM dogs to a state clinically indistinguishable
from normal without additional safety concerns. The rescue of
XLMTM muscle function with rAAV8-cMTM1 infusion at the
mid dose or above was also consistent with improved muscle re-
flexes and increased gait speed.
Joint movements used for gait require paired agonist and antagonist
muscle groups. We did not measure dramatic changes in hindlimb
extension and forelimb flexion torque in the mid- and high-dose co-
horts, possibly because these muscle groups contract against a load
during gait. Thus, loaded muscles in XLMTM may be able to main-
tain strength because of the stresses experienced, and did not improve
following rAAV8 infusion as much as the improvement observed in
non-loaded limb muscle groups. However, improvements in hin-
dlimb flexion and forelimb extension would still contribute to
improved gait because of improved flexion-extension symmetry at
the ankle joints. Furthermore, although we did not assess knee or
hip and shoulder joint muscle agonist-antagonist muscle groups, im-
provements in these non-studied muscle groups may have occurred
following mid- and high-dose rAAV8 infusion. The best evidence
to support this possibility is the near-normal gait observed in the
treated dogs after mid- or high-dose rAAV8 (see Movies S1, S2, S3,
and S4) that suggests better joint symmetry.
Because walking gait does not require maximal muscle torque, im-
provements in gait could be expected even for animals with more848 Molecular Therapy Vol. 25 No 4 April 2017modest increases in maximal muscle torque. There are a number of
reasons why gait analysis is complementary to (not redundant
with) muscle torque measurements. Gait assessment provides a func-
tional, behavioral measure in awake animals, while muscle torque iso-
lates function of a given muscle (or muscle group) and is assessed in
anesthetized animals. While both assessments provide slightly
different information, muscle torque might be considered as an iso-
lated measure of muscle performance, whereas gait reflects a more in-
tegrated measure of function. Similarly, respiratory function, which
involves the strength of various skeletal muscles including the dia-
phragm, was also comparable with normal controls in the mid- and
high-dose groups of treated XLMTM dogs. Furthermore, the normal-
ized myofiber morphology and orientation of the triads suggests exci-
tation-contraction coupling (ECC) improvement to support greater
muscle torque production. Therefore, these results identify an effec-
tive threshold dose of 2E14 vg/kg rAAV8-cMTM1 in dogs, consis-
tently measured by separate and distinct study endpoints, which is
similar to the dose (2E14 vg/kg, transgene-specific titration) that
we uniquely tested in our previous locoregional studies.7
We did not explore other doses below the rAAV8 mid dose (2E
14 vg/kg) or above the low dose (0.3E14 vg/kg); thus, we cannot
rule out the possibility that an intermediate dose (e.g., 1E14 vg/kg)
might result in a similar response profile. These results also suggest
a potential ceiling effect of rAAV8-cMTM1, which may be related
to the levels of myotubularin reached in skeletal muscles after vector
transduction. The amount of transgenic myotubularin in skeletal
muscles ranged from 15% to about 50% of WT endogenous levels
in mid-dose-treated dogs, whereas the higher vector dose resulted
in increased levels of myotubularin from 80% to 220%. Therefore,
it is likely that the presence of myotubularin in muscles at lower levels
than the endogenous protein is sufficient to rescue the XLMTM
phenotype, as suggested in our previous studies.7 Because the effec-
tive threshold dose of 2E14 vg/kg could present manufacturing
challenges for clinical trials, future preclinical efforts to test new
vectors that can achieve similar results, but at lower doses, would
be desirable. Furthermore, concerns about potential off-target effects,
such as in the liver, might provide additional rationale to investigate
liver detargeting alternative vectors designed by site-directed
mutagenesis, such as AAV2i8, or the muscle-specific AAV2i8G9
chimera.16,17 Alternatively, a concomitant short course of glucocorti-
coid therapy in patients could be used to prevent or control a poten-
tial transient hepatitis associated with systemic vector delivery, as
previously demonstrated in clinical trials using high doses of
rAAV8 or rAAV9.18,19
Intravenous delivery of rAAV8-cMTM1 led to efficient transduction
of skeletal muscles, diaphragm, heart, liver, and other tissues. We
observed a clear dose-dependent increase in VCN in the large panel
of analyzed tissues and a homogeneous biodistribution of the vector
in muscles across the body. Interestingly, the amount of rAAV8 vec-
tor in the liver of dogs was much lower compared with that reported
in other species, such as mice and nonhuman primates,20–22 and rep-
resented barely twice as much as that observed in muscles, which
www.moleculartherapy.orgindicates that differences in vector tropism exist among different an-
imal species.23 Although translation of body-wide gene therapy to
large-animal models of a generalized myopathy has remained chal-
lenging until recently,7 another report has demonstrated the feasi-
bility of muscle transduction following a simple intravenous injection
of a rAAV9 micro-dystrophin vector in a dog model of Duchenne
muscular dystrophy (DMD).24 In their reported study, which lasted
4 months, the vector was administrated at a comparable dose
(5–6E14 vg/kg) in two juvenile DMD dogs under immune suppres-
sion (cyclosporine and mycophenolate mofetil) prior and throughout
the entire experiment. Conversely, in our study, XLMTM dogs did
not require immune-suppression treatment, nor did they develop
humoral and/or cellular immune responses against the transgene
product or a T cell response against the vector capsid upon
rAAV8-cMTM1 administration, which probably explains the long-
lasting effect of gene transfer in this animal model. This difference
might be because of the nature of XLMTM pathology per se, because
contrary to DMD, XLMTM is not associated with either muscle
inflammation or with cycles of myofiber degeneration-regenera-
tion.11,25 In addition, the transgene product is unlikely to be recog-
nized as a foreign protein because untreated XLMTM dogs carry a
missense mutation with a residual amount of myotubularin in
tissues.26
Systemic administration of rAAV8-cMTM1 was well-tolerated
without adverse events in treated dogs, even at high dose (5E
14 vg/kg). Complete hematology counts, serum electrolytes or kidney
and liver function parameters remained within normal range in all
dogs throughout the study. In the high-dose group, where cardiac
myotubularin levels were 4-fold above normal, off-target effects of
rAAV8-cMTM1 on heart function (ejection fraction) were not de-
tected, even though a mild increase in left ventricle wall thickness
was found. Dogs that received mid-dose (2E14 vg/kg) rAAV8-
cMTM1 had increased LV thickness, but this change occurred later
than in the high-dose group. However, increase in wall thickness
was also observed in non-infused carrier and WT dogs. For example,
one of the female carrier dogs had LV wall thickness that increased
from mild to moderately thick from 27 to 52 weeks. Similarly, one
of the male control dogs had a mild LV septal wall thickness increase
at 27 weeks that progressed to moderate levels at 43 weeks. Thus, mild
variations in wall thickness were seen within each study group. The
interpretation of echocardiographic measurements to determine
chamber size, wall thickness, and LV systolic function was based on
published nomograms for dogs,14 but have not been established for
this specific breed ormix background. Therefore, it is unclear whether
these mild variations of LV thickness are suggestive of effects of
MTM1 overexpression in the heart or represent normal variations
that may be seen in growing dogs specific to this colony. Although
myotubularin protein levels in heart increased in response to vector
dosage, there did not appear to be any correlations with increasing
dose of rAAV8-cMTM1 and increasing wall thickness. These findings
in MTM1 mutant dogs contrast with our previous observations in
Mtm1 KO mice, where comparable systemic doses of rAAV8-
Mtm1 produced myotubularin expression at higher levels in heartleading to the presence of focal inflammatory infiltrates and fibrotic
lesions.7 In treated dogs, however, no such histological lesions were
observed. The observed heart lesions in mice may be explained by dif-
ferences in vector transduction and expression between species,
similar to differences seen previously betweenmouse and non-human
primate liver after systemic AAV administration.27,28 These lesions
were likely related to high levels of MTM1 in the heart of KO mice,
because administration of vectors detargeting cardiac expression of
the transgene reduced lesions in mutant mice (unpublished data).
This side effect may also be specific to mice; from a translational
perspective, it indicates that cardiac monitoring should be required
in XLMTM patients participating in future clinical trials.
In conclusion, our results demonstrate that systemic administration
of rAAV8-cMTM1 can correct the severe generalized muscle disease
in myotubularin-deficient dogs, defining a threshold dose in this an-
imal model, and support clinical trials of gene therapy in patients with
XLMTM by simple vector injection into a peripheral vein.
MATERIALS AND METHODS
Experimental Animals
XLMTM Labrador/Beagle dogs harboring a p.N155K missense muta-
tion in the MTM1 gene were obtained from a breeding colony at the
University of Washington as previously described.10,11,13,26,29 To
generate affected male and female dogs for the present study, two
hemizygous mutant males were previously infused with an AAV vec-
tor expressing the myotubularin (MTM1) gene as described previ-
ously.7 One year after AAV infusion, these affected males sired
both hemizygous mutant male and homozygous mutant female
offspring.
Animal Care
Dogs were housed in a temperature- and humidity-monitored envi-
ronment, maintained between 18C and 26C, and 30% and 70%,
respectively. An automatic lighting system provided a 12-hr diurnal
cycle occasionally interrupted for study-related activities. Dogs were
co- or group-housed and only separated, as necessary, for study-
related procedures. Dogs were fed once to twice daily (for a total of
approximately 2 cups/day). Animals were fasted as required by spe-
cific procedures (e.g., prior to blood draws for serum chemistry or
procedures involving sedation or anesthesia). Fresh drinking water
was provided ad libitum and was routinely analyzed for contami-
nants. Enrichment toys and treats were routinely supplied. In addi-
tion, trained staff exercised the animals daily.
XLMTM-affected dogs, both hemizygous males and homozygous fe-
males, show progressive clinical deterioration beginning at about
12 weeks of age. Because of difficulty in prehending and swallowing
food, or getting to the food bowl and water source, some dogs were
fed by hand. In general, affected XLMTM dogs remain ambulatory
until about 4 months of age. Affected dogs that can maintain sternal
recumbency without human aid are generally capable of moving to
their food and water source, and usually do not appear to be dis-
tressed. Criteria for humane euthanasia included inability to standMolecular Therapy Vol. 25 No 4 April 2017 849
Molecular Therapyor walk, and continued weight loss with pronounced muscle wasting
despite supplemental hand feeding.
Genotyping
Puppies were genotyped from DNA isolated from oral swabs.
Affected hemizygous males and homozygous mutant females car-
rying the MTM1 c.465C>A variant were identified using a TaqMan
assay as described previously.26 All genotypes were confirmed on
two independent specimens for each dog.
Study Design
Dogs were randomized into groups based on their genotype. XLMTM
dogs included mutant hemizygous males and homozygous females,
and both sexes were randomized into the study cohorts. The overall
flow of the experiment and handling of individual dogs are shown
in Figure S3. Investigators performing assessments were blinded to
the identities of animals and to their group assignments. Three
doses of rAAV8-cMTM1 were evaluated: 0.3E14, 2E14, and
5E14 vg/kg, denoted as low, mid, and high dose, respectively. After
randomization and baseline testing, three groups of XLMTM dogs
(n = 3 per group) were given a single intravenous infusion of
rAAV8-cMTM1 at 10 weeks of age: a low-dose group consisted of
male (n = 2) and female (n = 1) XLMTM dogs, a mid-dose group con-
sisted of all male (n = 3) XLMTM dogs, and a high-dose group con-
sisted of all male (n = 3) XLMTM dogs. Saline was administered in
a fourth group of male (n = 1) or female (n = 5) XLMTM dogs. A fifth
group of phenotypically normal (WT male [n = 3] or heterozygous
female [n = 3]) littermates served as untreated controls.
Vector Production
The recombinant AAV vector, rAAV8-cMTM1, containing the
canine myotubularin coding sequence (XM850116; NCBI) down-
stream of the human desmin promoter was produced after
baculoviral double infection of insect Sf9 cells and purified from total
cell culture using AVB affinity chromatography column (AVB
Sepharose high performance; GE Healthcare) as previously
described.7 The titer (vg/mL) was determined from DNase-resistant
particles by a qualified droplet digital real-time PCR assay. In the
present study, we used primers located in the transgene (forward:
50-GCCTCGCCCGGACTCTA-30; reverse: 50-CTCAGGATCGGT
GACCAGAGA-30; probe: 50-AGGATCCAGATCTAAGC-30 FAM-
MGB), instead of primers targeting the inverted terminal repeat
(ITRg) region, which was shown to significantly underestimate
genome titers.7 Capsid titers were determined by AAV8-specific
capsid ELISA (Progen). The vector was formulated in lactated
Ringer’s solution and controlled for sterility and purity.
Administration of rAAV8-cMTM1 or Control Vehicle
Following randomization and group assignments (Figure S3A),
affected XLMTM dogs were infused with a solution of rAAV8-
cMTM1 diluted in sterile 1 PBS or PBS alone infused into the
cephalic vein at 10 weeks of age. Three doses of rAAV8-cMTM1
were administered in units of viral vg per kilogram body weight
(vg/kg); capsid particles (cp/kg) were administered according to the850 Molecular Therapy Vol. 25 No 4 April 2017randomization protocol: low-dose, 0.3E14 vg/kg; 2E14 cp/kg;
mid-dose: 2E14 vg/kg; 9E14 cp/kg; high-dose: 5E14 vg/kg;
5E15 cp/kg. The maximum infusion volume was 5 mL/kg given
at a rate of 6.7 mL/min by infusion pump. Following administration,
the line was flushed with 1 mL of PBS to ensure complete delivery of
the test article.
Neurological Assessments
An NAS was assigned to each dog by a board-certified veterinary
neurologist (J.M.S.) as previously described,9 who was blinded to
the identity of the animals. Parameters assessed included cranial
nerve function, postural reactions, segmental spinal reflexes, gait
stride length, ability to run and jump, and muscle atrophy. Dogs
were observed for exercise intolerance or increased respiratory rate
and effort following activity. The presence or absence of a dropped
jaw (ability to hold the jaw in a closed position) was also noted.
Following each examination, a neurological severity score was as-
signed on a scale of 10 to 1, with 10 indicating a normal examination
and 1 indicating an inability to maintain sternal recumbency. How-
ever, predetermined humane euthanasia criteria were usually met
by an NAS score of 3. Results of neurological scoring for normal con-
trols and for some untreated XLMTM dogs have been reported.9
Segmental spinal reflexes assessed included the forelimb and hin-
dlimbwithdrawal, the extensor carpi radialis, the patellar, and the cra-
nial tibial reflexes. Reflexes were graded from 0 to 4, with 0 indicating
an absent response, 1 indicating a decreased response, 2 indicating a
normal response, 3 indicating an increased response, and 4 indicating
a clonic response. A score was assigned to each of the five reflexes, and
the five reflex scores for each dog were averaged. The average reflex
score for each dog was then used to create a mean reflex score (sum
of average reflex score for all dogs divided by the number of dogs
in the group) for the normal control group and for the XLMTM
groups at each time point.
Echocardiography and Doppler Examination
Comprehensive two-dimensional (2D) and Doppler echocardiogra-
phy examinations were performed in the left lateral position using
commercially available ultrasoundmachines (Vivid q or Vivid I; Gen-
eral Electric) equipped with a 3SRS sector phased array transducer.
All images were digitally stored for offline analysis (EchoPAC; Gen-
eral Electric), and measurements were performed on three consecu-
tive cardiac cycles and averaged. All LV measurements (short-axis
view) were taken from the right parasternal location by use of the
2D-guided anatomical M-mode at the level of the papillary muscles,
as recommended by the American Society of Echocardiography.30 LV
end-diastolic and end-systolic diameters, and LV posterior wall and
intraventricular septal wall thickness in diastole and systole were
measured. LV fractional shortening (FS) and LV ejection fraction
(EF) were calculated. From the apical four-chamber view, pulse-
wave Doppler was used to obtain maximal early and late diastolic
mitral flow velocities, and tissue Doppler imaging was obtained for
the medial and lateral mitral valve annulus measurements. Echocar-
diography measurements were interpreted to determine whether
www.moleculartherapy.orgmeasurements of chamber size, wall thickness, or LV systolic function
were within normal range, based on published nomograms.14
In Vivo Limb Strength
Contractile properties in canine hindlimb muscles were assessed
in vivo, as described previously.31,32 Contractile properties for canine
forelimb muscles were measured in an analogous manner as
described for dogs.33 In brief, hindlimb torque of anesthetized dogs
was measured by wrapping the foot to a pedal mounted on the shaft
of a servomotor that also functioned as a force transducer. Forelimb
torque was measured in a similar manner using a separate force trans-
ducer designed for the forelimb. Percutaneous nerve stimulation
activated limb muscles to either pull the paw up toward the body
or push the paw down toward the ground. Isometric contractions
were performed over a range of stimulation frequencies to determine
torque-frequency relationships.
Gait
An instrumented carpet (GAITRite Electronic Walkway; CIR Sys-
tems) was used to measure gait, as described previously.10 A trained
handler walked leashed dogs across the instrumented carpet at a
self-selected speed for 5–10 trials. Testing ended immediately if the
dog showed signs of fatigue. Fewer trials were collected for young
puppies or for very weak animals. Data were collected and analyzed
using software (GAITFour version 4.1; CIR Systems) with simulta-
neous video recording by a synchronized camera (Logitech) for qual-
ity control. Walks were selected based on consistency of pattern and
speed, as well as body position and behavior along the carpet. Spatio-
temporal measures of gait including gait speed and length were calcu-
lated, as described previously.10
Respiratory Function
Respiratory assessment was carried out in anesthetized dogs before
and after stimulation by a centrally acting stimulant, doxapram hy-
drochloride (1 mg/kg), as described previously.13 In brief, data were
collected in intubated dogs using a calibrated pneumotachometer,
where changes in pressure across the device determined airflow.
Flow-volume loops were created by replaying experimental data
through the appropriate analyzer (iox 2.8.0.13; EMKA Technologies)
and capturing 10 consecutive breaths during stimulation with doxap-
ram hydrochloride. Software (EMKA Technologies) calculated peak
inspiratory flow (PIF), peak expiratory flow (PEF), inspired volume
(IV), expired volume (EV), inspiratory time (TI), and expiratory
time (TE).
VCN and Transgene Expression
The number of vg per dg (VCN) was quantified from 32 ng of
total DNA by TaqMan real-time PCR using a LightCycler 480
(Roche). The canine b-glucuronidase gene was used for standardiza-
tion. Primers used for vg amplification were: 50-GCCTCGCCCG
GACTCTA-30 (forward), 50-CTCAGGATCGGTGACCAGAGA-30
(reverse), and 50-AGGATCCAGATCTAAGC-30 (probe). Primers
and probe used for b-glucuronidase amplification were: 50-ACGCT
GATTGCTCACACCAA-30 (forward), 50-CCCCAGGTCTGCTTCATAGTTG-30 (reverse), and 50-CCCGGCCCGTGACCTTTGTGA-30
(probe) (Applied Biosystems).
mRNA Expression
Tissues were homogenized using MagNa Pure LC RNA Isolation
Tissue Lysis Buffer (Roche), and total RNA was isolated using an
automated nucleic acid extraction instrument (MagNA Pure 96 Sys-
tem), followed by DNase digestion to minimize genomic DNA
contamination (DNA-Free DNA Removal Kit; Life Technologies).
One hundred nanograms of total RNA was used to perform a one-
step qRT-PCR using the LightCycler Multiplex RNA Virus Master
kit (Roche) and specific oligonucleotides and probes in a LightCycler
480 (Roche). The 60 s ribosomal protein L32 (RPL32) was used for
normalization. The sequences of the primers and probes were: vec-
tor-derived transcript: 50-GCCTCGCCCGGACTCTA-30 (forward),
50-CTCAGGATCGGTGACCAGAGA-30 (reverse), and 50-AGGATC
CAGATCTAAGC-30 (FAM-MGB) (probe); canine MTM1 tran-
script: 50-ATAAGTTTTGGACATAAGTTTGC-30 (forward), 50-CA
TTTGCCATACACAATCAA-30 (reverse), and 50-CGACGCTGA
CCGGTCTCCTA-30 (FAM Tamra) (probe); and canine RLP32
transcript: 50-TGGTTACGGGAGCAACAAGAAA-30 (forward), 50-
GCACATCAGCAGCACTTCA-30 (reverse), and 50-TGCTGCCCA
GTGGCTTCTGG-30 (VIC-QSY) (probe).
Immunoblotting
Proteins were extracted from tissues using a lysis buffer containing
10 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 2 mM Na orthovanadate, 100 mM NaF, 4 mM sodium pyro-
phosphate, 1% Triton X-100, 0.5% IGEPAL, and a protease inhibitor
cocktail (Roche Applied Science), and analyzed by SDS-PAGE
(NuPAGE Novex 4%–12% Bis-Tris gels; Invitrogen) and western
blotting as previously described.7 Membranes were probed with a
polyclonal antibody against the C terminus of canine myotubularin
(R1040; Genethon) and a mouse monoclonal antibody against
GAPDH (MAB374; Millipore) as internal control. Detection was
performed with a secondary antibody coupled to IRDye 680 (LI-
COR Biotechnology) and the Odyssey infrared imaging system
(LI-COR Biotechnology).
Heatmap Illustrations
For both the VCN and transgene data, the colors in the visualization
(Figure 7) reflect the average value for each anatomical part in its dose
category (low, mid, and high dose). Non-treated dogs were not used
for any calculations or depictions. For the VCN data, this average was
calculated over measurements from both sides of the dog. Further-
more, missing values were not included in the denominator when
calculating the average. The nine-class spectral color scale from Color
Brewer was employed to differentiate between average values for both
the VCN and the transgene expression data.34 Values that fall be-
tween given spectral scale color values are interpolated using the
interpolation function built into D3.js.35 When sorted in ascending
order, data for both the VCN and transgene expression data are linear
until a point where values begin to increase exponentially. To prevent
the color scale from being skewed toward these high-value outliersMolecular Therapy Vol. 25 No 4 April 2017 851
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the data to the spectral color scale and the remaining outlier values
to a separate dark red color. For depiction of VCN, values ranging
from 0 to 4 were mapped to the spectral color scale, which captures
92% of the data. Values greater than 4, which correspond to the re-
maining 8% of data, appear in a separate dark red color. For depiction
of transgene expression, values ranging from 0 to 3 were mapped to
the scale, which captures 95.5% of the data. Values greater than 3,
which correspond to the remaining 4.5% of data, appear in a separate
dark red color.
Humoral Immune Responses to the AAV8 Vector Capsid
An ELISA was used to detect IgG antibodies specific to the AAV8
capsid in serum samples collected from uninjected and rAAV8-
cMTM1-treated dogs, as previously described.36,37
The neutralizing assay was performed as previously described36–38
with some modifications. In brief, 96-well plates were seeded with
20,000 2V6.11 cells treated with Ponasterone (Invitrogen) for 24 hr.
The next day, a recombinant AAV8-CMV-luciferase reporter vector
was diluted in DMEM (Invitrogen Life Technology) and incubated
with 3.16-fold serial dilutions (1:1 to 1:316,000) of heat-inactivated
serum samples (at 56C for 30 min) for 1 hr at 37C. Subsequently,
the serum-vector mixtures were added to cells plated earlier and incu-
bated in DMEM plus 10% fetal calf serum (FCS) for 24 hr. Each sam-
ple was tested in triplicate. Cells were then washed in PBS and lysed
for 5 min with Bright-Glo Luciferase Assay system (Promega). The
luciferase activity was read on a luminometer. Transduction efficiency
was measured as relative light units. The values are presented as per-
centage of transgene activity compared with transduction of an equal
amount of vectors without serum pre-incubation. The neutralizing
titer was determined as the serum dilution at whichR50% inhibition
occurred.
Humoral Immune Response to Canine MTM1 Protein
A customized ELISA assay was developed to detect IgG antibodies
specific to the canineMTM1 protein in serum. In brief, an anti-canine
MTM1 antibody (R1040; Genethon) was diluted in coating buffer
(0.1 M carbonate buffer at pH 9.5) to a final concentration of
5.8 mg/ml. Two-fold serial dilutions (500 ng/ml to 7.8 ng/ml) of a
dog reference standard (Bethyl Laboratories) were used to build a
standard curve in the assay. After overnight incubation, blocking,
and washing steps, plates were incubated 1 hr at 37C with canine
MTM1 protein. Serum samples were diluted (1/200 and 1/20) in
blocking buffer and incubated 1 hr at 37C; then a secondary anti-
dog IgG-HRP-conjugated antibody was added to plates. Results in
this assay are expressed as a concentration of antibodies specific for
the canine MTM1 protein.
Cellular Immune Response to the rAAV8 Capsid and Canine
MTM1 Protein
Cellular immune responses specific to the AAV8 capsid in dogs were
monitored by IFN-g enzyme-linked immunospot (ELIspot) assays as
previously described.39852 Molecular Therapy Vol. 25 No 4 April 2017Tissue Collection
Muscle samples were collected and processed as described previ-
ously.40 For biopsies, tissue from the vastus lateralis, gastrocnemius,
biceps brachialis, and sartorius muscles were collected from normal
and XLMTM dogs at 10, 18, and 25 weeks of age (unless the an-
imal succumbed earlier to disease), and autopsy tissue collection
was performed when animals required euthanasia (age range 17–
27 weeks).
Histological Evaluation
Muscle histology was performed based on staining with H&E,
reduced nicotinamide adenine dinucleotide (NADH), and an
ATPase stain performed at pH 9.4. Slides were evaluated by a
board-certified anatomic pathologist and neuropathologist
(M.W.L.) with respect to the full range of possible pathologies. The
extent of pathology was scored based upon the approximate percent-
age of myofibers displaying XLMTM pathology as described in dogs6
(Figure S2). Scores were assigned as follows: grade 0 = no XLMTM
pathology, grade 1 = XLMTM pathology in %10% of fibers, grade
2 = XLMTM pathology in 11%–30% of fibers, grade 3 = XLMTM
pathology in 31%–60% of fibers, grade 4 = XLMTM pathology in
61%–80% of fibers, and grade 5 = XLMTM pathology in
81%–100% of fibers. The pathology scores of all muscles were aver-
aged for each dog as an indication of pathology across the entire
animal at a given time point. Formal quantitative studies were
performed on the vastus lateralis specimens only. Myofiber size was
evaluated on scanned H&E-stained slides and measured using an
automated technique developed in our prior work.41,42 The percent-
age of fibers with central nucleation and the percentage of fibers with
organelle mislocalization were manually scored using images of slides
stained with H&E or NADH, respectively. Muscle tissue (vastus
lateralis) was fixed in 2.5% glutaraldehyde, processed at the Medical
College of Wisconsin’s EM Core Facility, and evaluated at each
time point using a standard approach previously described.7,8
Comprehensive reports of pathological findings at the light and
EM level were prepared using an adaptation of the National Institute
of Neurological Disorders and Stroke (NINDS) Common Data
Elements muscle biopsy reporting form.43
Statistics
In this dose-escalation study, we used the Jonckheere-Terpstra non-
parametric statistic for an alternative of increasing trend across the
four dose groups (saline only, low-, mid-, and high-dose rAAV8-
cMTM1) versus no increasing trend. For each subject the difference
between the pre-infusion (week 9) and the post-infusion (week 17)
value was calculated for each measured variable. This change score
for each dog is used to calculate the trend statistic. There were six
dogs in the saline group and three dogs in each of the three dosing
groups. The number of animals that could be bred for this exploratory
investigation limited the overall number of XLMTM dogs; therefore,
the sample size was not based on statistical considerations. The p
values reported are not adjusted for multiplicity of tests and should
be interpreted in terms of consistency of effect. Statistical software
used was the open-source R language.44,45 One-way ANOVA
www.moleculartherapy.orgfollowed by Bonferroni’s multiple comparison post-test was used for
pathology readouts (Table S5).
Study Approval
Dogs were handled according to principles outlined in the NIH
Guide for the Care and Use of Laboratory Animals and as approved
by the University of Washington institutional animal care and use
committee (IACUC).
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